Researchers from the University of Leicester and Leicester's Hospitals announced recent success of a novel molecule called ONO/GS-4059 in Phase I first-in-human clinical trial against drug resistant forms of B-cell leukemia . Bruton’s tyrosine kinase (BTK) is intimately involved in multiple signal-transduction pathways regulating survival, activation, proliferation, and differentiation of B-lineage lymphoid cells.
Some antagonist against BTK has already been proven to be effective in treating B-cell malignancies, like The BTK inhibitor ibrutinib (PCI-32765) demonstrated high clinical activity in B-cell malignancies, especially in patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenstrom's macroglobulinemia (WM). Other BTK inhibitors in earlier clinical development include CC-292 (AVL-292), and ONO/GS-4059 are the other BTK antagonists that were…